TELA Bio, Inc. (TELA)
TELANASDAQ-GMMedical/Dental Instruments
$0.7850
-0.0750 (-8.72%) today
Regular session, Nov 13, 10:28 AM ET
- Market cap
- $35.47m
- P/E
- –
- EPS, last 4 quarters
- $-0.7000
- Dividend yield
- –
- Day range
- $0.7600 to $0.8700
- 52-week range
- $0.5011 to $1.50
- Average volume
- –
- Previous close
- $0.8600
Analysts
4 coveringBuy3 buy, 1 hold, 0 sell
Targets a year out average $1.75, +122.9% from here
Earnings
next estimate $-0.1600Next report
Dec 2025
+11.1%
Mar 2026
-50.0%
Jun 2026
-17.6%
Sep 2026
+31.6%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $20.87m | $19.06m | $19.29m | $18.96m |
| Gross profit | $13.76m | $12.52m | $13.94m | $12.31m |
| Operating income | -$6.65m | -$10.53m | -$9.28m | -$7.29m |
| Net income | -$9.04m | -$12.27m | -$11.26m | -$9.30m |
Last four quarters: revenue $78.18m, margin -53.6%, free cash flow -$34.39m
News
8 latest- TELA Bio (TELA) Q3 2026 Earnings Call TranscriptThe Motley Fool · 2 days ago
- TELA Bio, Inc. (TELA) Reports Q3 Loss, Beats Revenue EstimatesZacks · 3 days ago
- Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Lags Revenue EstimatesZacks · Nov 4, 2026
- Oculis Holding AG (OCS) Reports Q3 Loss, Lags Revenue EstimatesZacks · Nov 3, 2026
- Weekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data RTTNews · Oct 9, 2026
- TELA Bio Wins FDA 510(k) Clearance For Fully Resorbable Liora Scaffold RTTNews · Oct 5, 2026
- TELA Bio Says FDA Grants 510(k) Clearance For Liora Monofilament Scaffold Product RTTNews · Oct 5, 2026
- Craig-Hallum Initiates Coverage of TELA Bio at BuyFintel · Sep 25, 2026
The company
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- telabio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.